An Open-label, Observational, Prospective, Multicenter Study to Evaluate the LOng-teRm Efficacy and SafeTy of PerAmpanel as Monotherapy in SuBjects Age 4 Years and Older with FocaL Onset Seizures:PORTABLE Study
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy; Seizures
- Focus Therapeutic Use
- Acronyms PORTABLE Study
- 15 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2021 Status changed from not yet recruiting to recruiting.
- 26 May 2021 New trial record